Palvella announces Phase 3 SELVA topline results for QTORIN in lymphatic malformations; specifics not in filing excerpt

PALVELLA THERAPEUTICS, INC.

Topline data from Phase 3 SELVA study of QTORIN 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations announced on Feb 24, 2026.
Investor conference call held at 8:00 a.m. ET; presentation slides furnished as Exhibit 99.1.
Exact efficacy and safety endpoints not disclosed in this filing excerpt; full results expected in the presentation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.